High Level of Pre-Treatment HIV-1 Drug Resistance and Its Association with HLA Class I-Mediated Restriction in the Pumwani Sex Worker Cohort.
antiretroviral therapy
drug-resistant mutation
human immunodeficiency virus
human leukocyte antigen
next-generation sequencing technology
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
28 01 2022
28 01 2022
Historique:
received:
09
12
2021
revised:
17
01
2022
accepted:
18
01
2022
entrez:
26
2
2022
pubmed:
27
2
2022
medline:
15
3
2022
Statut:
epublish
Résumé
We analyzed the prevalence of pre-antiretroviral therapy (ART) drug resistance mutations (DRMs) in a Kenyan population. We also examined whether host HLA class I genes influence the development of pre-ART DRMs. The HIV-1 proviral DNAs were amplified from blood samples of 266 ART-naïve women from the Pumwani Sex Worker cohort of Nairobi, Kenya using a nested PCR method. The amplified HIV genomes were sequenced using next-generation sequencing technology. The prevalence of pre-ART DRMs was investigated. Correlation studies were performed between HLA class I alleles and HIV-1 DRMs. Ninety-eight percent of participants had at least one DRM, while 38% had at least one WHO surveillance DRM. M184I was the most prevalent clinically important variant, seen in 37% of participants. The DRMs conferring resistance to one or more integrase strand transfer inhibitors were also found in up to 10% of participants. Eighteen potentially relevant ( High levels of HIV drug resistance were found in all classes of antiretroviral drugs included in the current first-line ART regimens in Africa. The development of DRMs may be influenced by host HLA class I-restricted immunity.
Sections du résumé
BACKGROUND
We analyzed the prevalence of pre-antiretroviral therapy (ART) drug resistance mutations (DRMs) in a Kenyan population. We also examined whether host HLA class I genes influence the development of pre-ART DRMs.
METHODS
The HIV-1 proviral DNAs were amplified from blood samples of 266 ART-naïve women from the Pumwani Sex Worker cohort of Nairobi, Kenya using a nested PCR method. The amplified HIV genomes were sequenced using next-generation sequencing technology. The prevalence of pre-ART DRMs was investigated. Correlation studies were performed between HLA class I alleles and HIV-1 DRMs.
RESULTS
Ninety-eight percent of participants had at least one DRM, while 38% had at least one WHO surveillance DRM. M184I was the most prevalent clinically important variant, seen in 37% of participants. The DRMs conferring resistance to one or more integrase strand transfer inhibitors were also found in up to 10% of participants. Eighteen potentially relevant (
CONCLUSIONS
High levels of HIV drug resistance were found in all classes of antiretroviral drugs included in the current first-line ART regimens in Africa. The development of DRMs may be influenced by host HLA class I-restricted immunity.
Identifiants
pubmed: 35215866
pii: v14020273
doi: 10.3390/v14020273
pmc: PMC8879707
pii:
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Nat Med. 2016 Jun;22(6):606-13
pubmed: 27183217
Hum Immunol. 2001 Nov;62(11):1294-310
pubmed: 11704293
Clin Infect Dis. 2021 Oct 5;73(7):e2311-e2322
pubmed: 32785695
J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):47-54
pubmed: 21997204
Lancet Infect Dis. 2018 Mar;18(3):346-355
pubmed: 29198909
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5393-400
pubmed: 25453107
JAMA. 2011 Apr 6;305(13):1327-35
pubmed: 21467286
Tissue Antigens. 1999 Jul;54(1):69-82
pubmed: 10458325
AIDS. 2018 Sep 10;32(14):1927-1938
pubmed: 30048246
Clin Infect Dis. 2006 Jun 1;42(11):1608-18
pubmed: 16652319
Science. 2002 May 24;296(5572):1439-43
pubmed: 12029127
PLoS One. 2018 Dec 18;13(12):e0206177
pubmed: 30562356
Lancet HIV. 2018 Aug;5(8):e438-e447
pubmed: 30025681
AIDS. 2021 Jun 1;35(7):1083-1089
pubmed: 33635845
AIDS. 2017 Sep 10;31(14):1935-1943
pubmed: 28650381
Clin Infect Dis. 2013 Oct;57(7):1051-5
pubmed: 23797286
PLoS One. 2009 Aug 19;4(8):e6687
pubmed: 19690614
JAMA. 2019 Feb 5;321(5):451-452
pubmed: 30629090
PLoS One. 2017 Feb 8;12(2):e0171124
pubmed: 28178281
Antivir Ther. 2019;24(8):595-601
pubmed: 32125280
Top Antivir Med. 2019 Sep/Oct;27(3):111-121
pubmed: 31634862
EClinicalMedicine. 2020 Jan 14;18:100239
pubmed: 31956856
J Infect Dis. 2020 Apr 27;221(10):1584-1597
pubmed: 31809534
J Acquir Immune Defic Syndr. 2011 Feb 1;56(2):109-17
pubmed: 21107269
Pan Afr Med J. 2020 Dec 03;37:311
pubmed: 33654530
Infect Genet Evol. 2016 Dec;46:292-307
pubmed: 27587334
AIDS Res Hum Retroviruses. 2008 Jun;24(6):865-72
pubmed: 18544023
AIDS Res Hum Retroviruses. 2008 Nov;24(11):1455-60
pubmed: 19032067
AIDS. 2012 Jan 14;26(2):185-92
pubmed: 22179227
PLoS One. 2011;6(8):e23091
pubmed: 21886779
JAMA. 2016 Jul 12;316(2):171-81
pubmed: 27404185
Ann Ist Super Sanita. 2010;46(1):5-14
pubmed: 20348614
PLoS One. 2019 Feb 13;14(2):e0210559
pubmed: 30759103